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Abstract 
Background: 
Primary care clinicians often struggle to identify women who experience domestic violence and 
abuse (DVA) and are uncertain about how to respond when DVA is disclosed. The 
Identification and Referral to Improve Safety (IRIS) randomised controlled trial tested the 
effectiveness of a primary care training and support intervention to improve the response to 
women experiencing DVA, and found it to be cost-effective.  As a result, the IRIS programme 
has been implemented across the UK, generating   data  on costs and effectiveness outside a 
trial context.  
Aim:  
To evaluate the cost-effectiveness of the implementation of the IRIS programme using up-to-
date real-world information on costs and effectiveness from routine clinical practice.  
Design and Setting:  
Cost–utility analysis in UK general practices, including data from six sites which have been 
running IRIS for at least two years  across England. 
Method: 
A Markov model was constructed to estimate mean costs and quality-adjusted life-years 
(QALYs) of IRIS versus usual care per woman registered at a general practice from a societal 
and health service perspective with a ten-year time horizon.  
Results:  
The IRIS programme saved £14 per woman aged 16 or older registered in general practice (95% 
CI [-£151; £37]) and produced QALY gains of 0.001 per woman (95% CI [-0.005; 0.006]). The 
incremental net monetary benefit was positive both from a societal and NHS perspective (£42 
and £22 respectively) and the IRIS programme was cost-effective in 61% of simulations using 
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real life data when the cost-effectiveness threshold was £20 000 per QALY gained as advised 
by NICE.  
Conclusion:  
The IRIS programme is likely to be cost-effective and cost-saving from a societal perspective 
in the UK and cost effective from a health service perspective, though there is considerable 
uncertainty surrounding these results, reflected in the large confidence intervals. 
 
Strengths and limitations of this study 
 Primary care clinicians often struggle to identifywomen who experience domestic 
violence and abuse (DVA) and are uncertain about how to respond when DVA is 
identified.  
 The Identification and Referral to Improve Safety (IRIS) trial tested the effectiveness of 
a primary care training and support intervention to improve the response to women 
experiencing DVA.  
 Using up-to-date data on costs and effectiveness from routine clinical practice the 
national implementation of the IRIS programme is likely to be cost-effective and even 
cost-saving. 
  
 6 
Introduction  
The lifetime prevalence of domestic violence and abuse (DVA) against women varies 
internationally from 15% to 71% (1). In the United Kingdom, in the year ending March 2017, 
7.5% of women (1.2 million) experienced domestic abuse. Women who experience DVA suffer 
chronic health problems including gynaecological problems, gastrointestinal disorders, 
neurological symptoms, chronic pain, cardiovascular conditions and mental health problems 
(2-5). In 2012, the cost of DVA in the UK, including medical and social services, lost economic 
output and emotional costs, was estimated to be £11 billion (6). While such estimates highlight 
the importance of DVA as a public health and clinical problem, information on cost-
effectiveness is needed to make an economic case for investment in DVA interventions in health 
care, particularly when health systems are dominated by austerity.  
 
The Identification and Referral to Improve Safety (IRIS) trial tested the effectiveness of a 
training and support intervention for general practice teams in two English cities (7). 
Discussions about DVA between  clinicians and patients were 22 times greater in the 
intervention practices compared with the control practices and referrals received by DVA 
agencies were six times greater. The IRIS programme can now  be commissioned across the 
UK: as of December 2016, 34 UK areas had commissioned IRIS; more than 800 GP practices 
nationally have had IRIS training, and over 5,000 women have been referred in to support 
services by IRIS since 2010.  
 
 The cost-effectiveness of the IRIS trial was assessed using data from the trial and the 
programme was estimated to be good value for money (8). Given its national implementation , 
IRIS became a  real-life, long-term intervention, raising the need for a new economic evaluation 
outside the trial context. The aim of this study was to evaluate the cost-effectiveness of the IRIS 
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programme now that it has been implemented across the UK. Our estimates use up-to-date 
figures from an MRC phase IV observational pragmatic implementation study on costs and 
effectiveness from routine clinical practice and the most up-to-date model input parameters, 
including a recently updated Cochrane review of domestic violence advocacy (9). 
 
Methods 
Overview of economic evaluation 
This was a cost–utility analysis, comparing IRIS with usual care in general practices. The 
outcome measure was quality-adjusted life years (QALYs), as recommended for economic 
evaluations in the UK (10). The main analysis was  from a societal perspective, as many of the 
costs of DVA are borne outside the health system; we also estimated cost utility from an NHS 
perspective.  Costs were calculated in 2015/16 UK£. We calculated costs and benefits  over a 
10-year time horizon, with future costs and outcomes  discounted at an annual rate of 3.5% 
(10). 
 
Model structure 
We developed a Markov model (Figure1) based on the previous analysis (8). The model has 
five states and the cycle length was six months; this length was chosen as it reflects the average 
amount of time women stay in contact with DVA advocacy services. A hypothetical cohort of 
10,000 women aged 16 years or older was simulated moving between the states (Figure 1). 
Other than death, which is an absorbing state, women can transition between each of the other 
states 'Not abused', 'Abused but not identified', 'Abused and identified, seeing advocate 
educator', 'Abuse and identified, not seeing advocate educator'.  
 
Intervention 
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The IRIS programme is a multi-component intervention that has been described in detail 
elsewhere (7, 8). In brief, it consists of two two-hour multidisciplinary training sessions, for the 
practice clinical team and one hour training for reception and ancillary staff.  They are delivered 
jointly by an IRIS advocate educator from a local collaborating specialist DVA agency, 
alongside a clinician interested in DVA,  the IRIS clinical lead. The advocate educator is central 
to the intervention, combining a training and support role to the practices with provision of 
advocacy to women referred. Other intervention components include a HARK template1 in the 
electronic medical record triggered by entry of  clinical problem codes (such as depression, 
anxiety, irritable bowel syndrome, pelvic pain and assault), an explicit referral pathway to a 
named IRIS DVA advocate educator, and publicity materials about DVA visible in practices. 
Patients are usually seen at the referring general practice, enhancing safety and confidentiality. 
 
Prevalence of domestic abuse 
The proportion of women aged 16 years or older experiencing abuse was estimated based on 
published epidemiological data. This was taken from a cross sectional study carried out by 
Richardson and colleagues in east London (12), which reported  a prevalence of 0.17 in the 
population of women consulting a general practitioner or practice nurse. This is an estimate of 
the prevalence of DVA in general practice, generalizable for England. . 
 
Transition probabilities 
There are eight transitions between states in the model. Transition probabilities were obtained 
using observational data from the IRIS programme, the MOSAIC (MOthers' Advocates In the 
Community) programme (7, 13), the Office for National Statistics (14, 15)  and Health & Social 
                                                          
1 For more information of the HARK template, please see 11. Sohal H, Eldridge S, Feder G. The sensitivity and 
specificity of four questions (HARK) to identify intimate partner violence: a diagnostic accuracy study in general 
practice. BMC family practice. 2007;8(1):49. 
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Care Information Centre (16), and a Cochrane review (9), evaluating the reduction of any type 
of domestic abuse with any type of advocacy. Observational data were obtained from 
commissioned IRIS sites that have been running for two years or more, , where there was at 
least one full-time equivalent advocate educator and 20 general  practices trained. It included 6 
clinical commissioning groups (CCGs) in northern England, south-west England and London. 
Given the inclusion criteria, the sites represent  the implementation of the programme. . Table 
1 provides the parameter values and their respective sources. Where no data were available, we 
have calculated estimates using the model calibration method described below. 
 
Model calibration 
Because of uncertainty surrounding transition probabilities from Not abused to Abused but not 
identified and vice versa, we used the prevalence of abuse (17%) estimated in Richardson and 
colleagues’ study (12), to calibrate the model. The model was run for 3000 cycles, assuming 
that thereafter the number of women in each state would remain constant. The transition 
probabilities from Not abused to Abused but not identified and vice versa were changed until 
the proportion of women in the Not abused state exactly reflected the observed prevalence (100-
17=83%). The initial distribution of women in the three Abused states was also determined by 
this process. 
 
Utilities 
Each state in the Markov model was associated with a utility score, which consisted of a general 
measure of health-related quality-of-life (17), allowing us to measure QALYs associated with 
IRIS and the comparator based on the proportion of women in each health state in each of the 
20 6-monthly cycles in the model, totalling 10 years. The utility score of women who were not 
abused was assumed to be 0.85 (18). Wittenberg and colleaagues. conducted  a cross-sectional 
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survey to estimate community preferences for health states resulting from intimate partner 
violence. Using a UK-based algorithm, they found the utility of women experiencing any abuse 
was 0.64. When the severity/frequency of violence was low, the mean utility was 0.65 and when 
the severity/frequency was moderate or severe the mean utility was 0.63. For women who were 
abused in our model, we assumed this was moderate to severe, giving a utility score of 0.63 
(19). For women seeing an advocate educator, we used the utility value of women with low 
abuse (0.65), implying that seeing an advocate educator slightly increased their quality-of-life 
scores.  
 
Costs 
We included: intervention costs, costs of onward referral, and costs associated with abuse 
(including costs to the UK National Health Service (NHS), lost economic output, costs to the 
criminal/civil justice system, and personal costs).  
 
One IRIS advocate educator typically provides training, support and advocacy services for 24 
general practices at any one point in time. Intervention costs were calculated based on the actual 
budget of the IRIS programme in the six sites (including advocate educator salaries, travel, 
recruitment, laptop, telephone, publicity, clinician consultancy, evaluation and central 
management costs) at a total six month cost across all sites of £272,613. This was divided by 
the number of registered women aged 16+ in IRIS-trained general practices in these sites 
(595,902). Costs of onward referral from the advocate educator was based on the finding of 
contact time from the IRIS trial, in which an onward referral was given to 57% of women in 
contact with an advocate educator and 63% of these women accepted this. Therefore, although 
costs of onward referral were based on  current  budgets and salaries, the proportion of contact 
was obtained from the trial estimates. Total costs per onward referral were therefore £861. 
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Taking into account the proportion of women given a referral and accepting it, and inflating it 
to 2015/16 UK£, average costs of advocate educator contact per abused woman  were £312. 
 
Costs associated with intimate partner violence in the UK are described by Walby and Olive 
(6). In their report, costs of lost economic output, health services, criminal justice system, civil 
justice system, social welfare, personal costs, specialised services and physical/emotional 
impact were individually reported, and total costs were €13,732 million (£11 billion) in 2012. 
We excluded costs of physical/emotional impact (€6,614 million), as they were not financial 
costs, but consisted of monetary valuing of health status, which in cost-effectiveness models 
ought to be captured in terms of QALYs; these were also not included in the original cost-
effectiveness analysis. The remaining costs were converted to UK£ and inflated to 2015/16. 
Total costs per six months were £2,933 million. Based on the 2015 Crime Survey for England 
and Wales, it was estimated that 1.3 million women experienced intimate partner violence in 
2015/16 in the UK (20). Mean costs per abused woman were therefore £2,043. We assumed 
that the costs of intimate partner abuse are similar to the costs of abuse by other family 
members, and that the costs would not differ between identified or unidentified abuse.  In 
sensitivity analyses we have allowed the costs of identified abuse to increase or decrease by 
10% compared to abuse that was not identified; similarly the costs of Abused and identified, 
seeing advocate educator were allowed to increase or decrease by 25%. 
 
Cost-utility analysis 
Costs and utilities were applied to each health state. Total costs and QALYs for the hypothetical 
cohort were generated for the IRIS programme and the control group. The main outcome was 
the incremental costs per QALY gained. In the UK an intervention is generally considered cost-
effective when the incremental costs per QALY gained are less than £20,000 (10). We also 
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presented the results of cost-effectiveness analysis in terms of incremental net monetary benefit 
(NMB). This was calculated as the mean incremental QALYs per woman registered at the 
general practice accruing to IRIS multiplied by the decision-makers’ maximum willingness to 
pay for a QALY (assumed to be £20,000), minus the mean incremental cost per woman. 
Negative incremental NMBs indicate that usual care was preferred on cost-effectiveness 
grounds and positive incremental NMBs favour IRIS.  
The cost-utility analysis was conducted using pooled national data, but we have also evaluated 
the cost-effectiveness at different local sites. We allowed all parameters, including costs and 
benefits, to vary across sites and reported them individually. 
 
Sensitivity analysis 
All parameters were varied in a one-way sensitivity analysis, using lower and upper limits based 
on 95% confidence intervals. We undertook a probabilistic sensitivity analysis, drawing random 
samples from the probability distributions of all parameters in 1,000 simulations. The 
proportion of simulations with an incremental cost per QALY gained below the cost-
effectiveness threshold was calculated for different values, ranging from £0 to £50,000. The 
results were presented in a cost-effectiveness acceptability curve. 
 
Results 
Base case 
Parameter values used in the base case analysis are shown in Table 1. Over the ten-year time 
horizon, mean total costs per woman were £4,416 in the intervention group, compared to £4,430 
in the control group (Table 2(a)). The IRIS programme therefore saves £14 per woman aged 16 
and older registered to GP practices, from a societal perspective over 10 years. Total QALYs 
per woman were 0.001 higher in the intervention group (6.671) than in the control group 
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(6.669). Because the intervention was associated with lower costs and greater effectiveness the 
incremental cost per QALY gained was negative (i.e. IRIS dominates current practice as it is 
both cost-saving and more effective than usual care) and the incremental NMB was positive 
(£42). The incremental NMB was also positive (£22) when using an NHS-only perspective 
(Table 2(b)). 
 
Table 2 also presents the results for each site. The table shows that IRIS dominated current 
practice, from a societal perspective, in sites 1, 2, 3 and 4, with an incremental net monetary 
benefit (NMB) of £41, £89, £29 and £59 respectively. From a NHS perspective, only in site 1 
did IRIS dominate current practice, although it was cost-effective, using the threshold advised 
by NICE of £20,000 per QALY gained, in sites 2 (ICER £2,585 per QALY gained), 3 (ICER 
£3,055 per QALY gained) and 4 (ICER £8,317 per QALY gained). IRIS was found to be cost-
effective (ICER £5,882 per QALY gained) and borderline cost-effective (ICER £21,229 per 
QALY gained) from a societal and NHS perspectives respectively in site 5, and it was not cost-
effective from either perspective in site 6 (ICER £52,557 per QALY gained and ICER £64,427 
per QALY gained respectively). 
 
Sensitivity analyses 
Across all sites combined, results were most sensitive to varying the transition probability from 
Abused but not identified to Not abused. When in the control arm this was varied from 0.049 to 
0.051, the incremental NMB varied from £110 to -£26 (Figure 2). When it was varied similarly 
in the intervention arm, the incremental NMB varied from -£25 to £109. Figure 2 shows the 12 
parameters that when varied had the highest impact on the incremental NMB.  
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Incremental costs and QALYs varied widely in probabilistic sensitivity analyses. The 95% 
confidence interval for incremental costs was -£151 to £37, for incremental QALYs it was -
0.005 to 0.006 and for the incremental NMB it was -£247 to £351.  Figure 3(a) shows a scatter 
plot of the incremental costs and incremental QALYs from the 1,000 simulations. The IRIS 
programme is cheaper and more effective than the absence of the programme (usual care) , 
dominating current practice in 35% of the simulations and was dominated by the absence of the 
programme  in 18% of the simulations. The IRIS programme was cost-effective in 61% of 
simulations when the cost-effectiveness threshold was £20,000 (Figure 3(b)).  
 
Discussion 
Summary 
We found that the IRIS GP training and service programme is likely to be cost-effective and 
cost-saving in the UK compared to usual care. There is considerable uncertainty surrounding 
these results, but the probability that IRIS is cost-effective was more than 60% at the cost-
effectiveness threshold commonly used in the UK. IRIS was more cost-effective when costs 
were measured from a societal perspective as the cost savings from reducing DVA were higher.  
IRIS was also cost-effective when taking an NHS-only perspective. There was some variation 
in value for money between sites.  
 
Comparison with existing literature 
We contacted researchers in the field and searched the NHS Economic Evaluations Database 
and the HTA Database at the Centre for Reviews and Dissemination (21) for cost-effectiveness 
analyses of DVA programmes using the search terms “domestic violence” and “cost*” 
(28/08/2017). We  identified four economic impact studies, all using modelling methods: ), one 
based on the pilot of the IRIS trial (22), another based on the main trial (7), the third based on 
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an evaluation  of  independent domestic violence Advisors (IDVA), and the fourth of a trial of 
cognitive trauma therapy for abused women who have left the abusive relationship.  . All the 
studies found the interventions  cost-effective, despite uncertainty. Our findings are consistent 
with these previous studies. Our study is the only one that analyses the economic impact of a 
primary care-based programme implemented outside of trial settings.  
 
Strengths and limitations 
Our analysis has the strength of being based on a previously published cost-effectiveness 
model, updated with real-life data. Importantly, intervention costs and the probability of 
referral with IRIS were based on actual clinical practice, rather than in a research setting. We 
also had new data for the probability of identifying abuse and for what happened to women 
who were abused in current practice without the programme. However, it was not possible to 
update all parameter values. In particular, we were unable to update the utility value 
estimates, although in the sensitivity analysis, we have allowed these to vary and results were 
relatively stable.  Costs of the intervention were calculated by dividing the total costs of the 
programme over all registered women in practices with the IRIS programme. Many of these 
women will never experience abuse and therefore cannot directly benefit from the 
programme. If programme costs were divided over women experiencing abuse only, mean 
costs per woman would be higher. However, the QALYs gained would also be higher, as 
these are also calculated for all women in the practices rather than just those who were 
abused. In fact we have attempted to calculate these results dividing cost and QALYs over 
women experiencing abuse and the final ICER was unchanged, as both the numerator and 
denominator change by the same proportion. We did not include any impact of the IRIS 
programme on children exposed to DVA, as to our knowledge, there are no available cohort 
studies focusing on the cost and benefits of DVA interventions for this population which 
might mean that we have underestimated the programme’s cost-effectiveness. This was also 
highlighted in the NICE economic analysis of interventions to reduce incidence and harm of 
DVA: “It can be expected there are likely to be additional benefits such as [to] the children 
and wider family members of victims of domestic violence (p.11) 
Another limitation is that we have used mainly data on short-term outcomes, although modelled 
long-term outcomes. There is unfortunately little data on long-term outcomes of DVA and the 
effect of advocacy, although it is generally agreed that effects last for a long time.  
 
Implications for research and/or practice 
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The IRIS programme is likely to be cost-effective and cost-saving in the UK. In order to 
decrease uncertainty around the cost-effectiveness estimates of IRIS and programmes like it, 
more data  are needed on the utilities of women identified and women seeing an advocate and 
on long-term outcomes associated with DVA. Furthermore, future research should endeavour 
to understand the impacts and economic burden of DVA on exposed children, other family 
members and friends. 
Finally, our study has shown that there is moderate variation in the value for money of IRIS 
across different sites, implying qualitative research could focus on identifying the causes of 
such variation, in order to reduce it. 
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Table 1. Model input parameters: probabilities; utilities; and, costs. 
Parameter Base case value Lower limit Upper limit Distribution Source 
IRIS trial 
base value1 
Probabilities       
Proportion of women experiencing abuse 0.17 0.147 0.194 Beta (12) 0.17 
Starting distribution for women who are abused       
Abused and identified, seeing advocate educator 0.003¶ 0 0.0066 Uniform * - 
Abused and identified, not seeing advocate educator 0.033¶ 0 0.0660 Uniform * - 
Abused but not identified 0.964¶ - - Uniform Complement - 
Transition probabilities       
Not abused to Abused but not identified 0.0037¶ 0.0004 0.0106 Dirichlet * 0.0075 
Not abused to Dead 0.00551¶ 0.0010 0.0136 Dirichlet (13, 15) 0.0058 
Stay in Not abused 0.9908¶ - - Dirichlet Complement 0.9867 
Abused but not identified to Not abused (control) 0.0500¶ 0.0450 0.0553 Dirichlet * 0.025 
Abused but not identified to Abused and identified, not 
seeing advocate educator (control) 0.0027¶ 0.0016 0.0040 Dirichlet 
IRIS-
programme 
local sites 
0.0094 
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Abused but not identified to Abused and identified, seeing 
advocate educator (control) 0.0005¶ 0.0001 0.0011 Dirichlet 
IRIS-
programme 
local sites 
0.0016 
Abused but not identified to Dead (control) 0.00554¶ 0.0039 0.0074 Dirichlet (13, 15) 0.0059 
Stay in Abused but not identified (control)  0.9444¶  - - Dirichlet Complement 0.9581 
Abused but not identified to Not abused (intervention) 0.0500¶ 0.0450 0.0553 Dirichlet * 0.025 
Abused but not identified to Abused and identified, not 
seeing advocate educator (intervention) 0.0109¶ 0.0086 0.0135 Dirichlet 
IRIS-
programme 
local sites 
0.0207 
Abused but not identified to Abused and identified, seeing 
advocate educator (intervention) 0.0056¶ 0.0040 0.0076 Dirichlet 
IRIS-
programme 
local sites 
0.0101 
Abused but not identified to Dead (intervention) 0.00554¶ 0.0039 0.0074 Dirichlet (6) 0.0059 
Stay in Abused but not identified (intervention)  0.9419 ¶  - - Dirichlet  Complement 0.9383 
Abused and identified, seeing advocate educator to Not 
abused 0.1408¶ 0.0707 0.2301 Dirichlet (13) 0.0888 
Abused and identified, seeing advocate educator to Dead 0.00554¶ 0.0000 0.0309 Dirichlet (13, 15) 0.0059 
Stay in Abused and identified, seeing advocate educator  0.8536¶  - - Dirichlet  Complement 0.9053 
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Abused and identified, not seeing advocate educator to 
Not abused 0.0781¶ 0.0136 0.1912 Dirichlet (13) 0.0717 
Abused and identified, not seeing advocate educator to 
Dead 0.00554¶ 0.0000 0.0438 Dirichlet (13, 15) 0.0059 
Stay in Abused and identified, not seeing advocate 
educator 0.9163¶ - - Dirichlet Complement 0.9223 
Utilities       
Not abused 0.85 0.840 0.860 Beta (18) - 
Abused but not identified 0.63 0.503 0.749 Beta (19) - 
Abused and identified, seeing advocate educator 0.65 0.518 0.771 Beta (19) - 
Abused and identified, not seeing advocate educator 0.63 0.503 0.749 Beta (19) - 
Costs       
Costs of the intervention, per women registered, per 6 
months 
£0.46¶ £0.01 £1.69 Gamma IRIS-
programme 
local sites 
£0.55 
Cost of onward referral, once £312¶ £8 £1127 Gamma IRIS-
programme 
£298 
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local sites & 
(8) 
Cost of Abused but not identified £2043 £52 £7536 Gamma (6) £4721 
Weighted costs Abused and identified, seeing advocate 
educator 1 0.75 1.25 Gamma Assumption - 
Weighted costs Abused and identified, not seeing 
advocate educator 1 0.9 1.1 Gamma Assumption - 
Costs are in 2015/16 UK£.  
* Internal calculation based on model calibration. 
¶ Value updated from Devine et al (8). 
1 Values obtained from Devine et al (8). 
      
  
 
 
 24 
Table 2. Base case results. 
 (a) Societal perspective (b) NHS-only perspective 
National IRIS (pooled results) Costs QALYs Cost-effectiveness Costs QALYs Cost-effectiveness 
Intervention (IRIS programme) £4416 6.671  £1238 6. 671  
Control (no programme) £4430 6.669  £1232 6. 669  
Difference (intervention vs. control) -£14 0.001 
-ve (intervention 
dominates control) £6 0.001 
£3913 per QALY 
gained 
Incremental NMB*   £42   £22 
Local site 1       
Intervention (IRIS programme) £4318 6.671  £1231 6.671  
Control (no programme) £4334 6.669  £1232 6.669  
Difference (intervention vs. control) -£16 0.001 
-ve (intervention 
dominates control) -£1 0.001 
-ve (intervention 
dominates control) 
Incremental NMB*   £41   £26 
Local site 2       
Intervention (IRIS programme) £4305 6.673  £1240 6.673  
Control (no programme) £4333 6.670  £1232 6.670  
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Difference (intervention vs. control) -£28 0.003 
-ve (intervention 
dominates control) £8 0.003 
£2585 per QALY 
gained 
Incremental NMB*   £89   £54 
Local site 3       
Intervention (IRIS programme) £4325 6.671  £1235 6.671  
Control (no programme) £4334 6.670  £1232 6.670  
Difference (intervention vs. control) -£9 0.001 
-ve (intervention 
dominates control) £3 0.001 
£3055 per QALY 
gained 
Incremental NMB*   £29   £17 
Local site 4       
Intervention (IRIS programme) £4326 6.672  £1253 6.672  
Control (no programme) £4334 6.669  £1232 6.669  
Difference (intervention vs. control) -£8 0.003 
-ve (intervention 
dominates control) £21 0.003 
£8317 per QALY 
gained 
Incremental NMB*   £59   £30 
Local site 5       
Intervention (IRIS programme) £4337 6.670  £1244 6.670  
Control (no programme) £4332 6.669  £1232 6.669  
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Difference (intervention vs. control) £4 0.001 
£5882 per QALY 
gained £12 0.001 
£21229 per QALY 
gained 
Incremental NMB*   £6   £0 
Local site 6       
Intervention (IRIS programme) £4395 6.671  £1307 6.671  
Control (no programme) £4334 6.670  £1232 6.670  
Difference (intervention vs. control) £61 0.001 
£52557 per QALY 
gained £75 0.001 
£64427 per QALY 
gained 
Incremental NMB*   -£38   -£52 
NMB = net monetary benefit. QALY = quality-adjusted life year. Costs are in 2015/16 UK£. Numbers may not sum due to rounding. 
*Measured at a willingness to pay for a QALY of £20 000. 
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Figure 1. Health states and movement between health states in Markov model. 
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The model starts with all women in either the ‘Not abused’ state or one of the states associated with abuse, based on the prevalence of DVA (see 
text). Women in the ‘Not abused’ state could stay in this state, move to ‘Abused but not identified’ or die from any cause. Once women were in 
the ‘Abused but not unidentified’ state, they could stay in that state, move back to ‘Not abused’, move to ‘Abused and identified, seeing 
advocate’ or ‘Abused and identified, not seeing advocate’ or die. Women in the ‘Abused and identified’ states could stay in these states, move 
back to ‘Not abused’ or die.  
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Figure 2. Univariate sensitivity analysis. 
 
All analyses are as for the base case analysis with univariate adjustment of the parameters listed (see text). Results are point estimates of the 
incremental net monetary benefit (NMB) of the intervention vs. control. The incremental net monetary benefit is calculated at a maximum 
willingness to pay for a QALY of £20 000. 
  
-40 -20 0 20 40 60 80 100 120
Abuse Unidentified to No Abuse (control) (0.049-0.051)
Abuse Unidentified to No Abuse (intervention) (0.049-0.051)
Utility Abuse unidentified (0.503-0.749)
Cost of Abuse Unidentified, per 6 months (£52-£7536)
Abuse Unidentified to dead (control) (0.005-0.006)
Abuse Unidentified to dead (intervention) (0.005-0.006)
Abuse Identified and seeing advocate to No Abuse (0.071-0.230)
Utility Identified and seeing advocate (0.518-0.771)
Costs per woman registered, per 6 months (£0.01-£1.69)
Abuse Identified not seeing advocate to No Abuse (0.014-0.191)
Abuse Identified and seeing advocate to dead (0.000-0.031)
Utility Identified not seeing advocate (0.503-0.749)
Net monetary benefit (£)
NMB for lower limit…
NMB for upper limit…
Base case value incremental NMB: £74 
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Figure 3. Probabilistic sensitivity analysis. 
 
  
(a) Scatter plot of incremental costs and incremental QALYs from 
1000 simulations 
(b) Cost-effectiveness acceptability curve showing the probability that the 
intervention is cost-effective vs. control at different values of the maximum 
willingness to pay for a QALY 
QALY = quality-adjusted life year. Costs are in 2015/16 UK£. 
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